All News
What are the Early Stages of Lupus?
Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? During the lupus pod at RheumNow Live 2024, Dr. David Karp discussed the spectrum of autoimmune disease and the confusing terminology that is used with the complex world of early autoimmune disease. He cautioned against the traditional use of phrases such as incomplete lupus or undifferentiated connective tissue disease, which are heterogeneous and poorly defined.
Read Article
Sex Disparities in PsA/SpA
Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.
Read Article
Congratulations to Dr. Megan Clowse - named the new chief of the Division of Rheumatology and Immunology at Duke University School of Medicine, Durham, N.C. !! @clowse https://t.co/d6iCEHlF3F
Dr. John Cush RheumNow ( View Tweet)
Obesity increase risk of psoriasis
Obesity increase risk of PsA in psoriasis pts RWCS24 https://t.co/Wt9h0QLbKH
Dr. John Cush RheumNow ( View Tweet)
Obesity is assoc w higher CRP.
Losing weight lowers CRP RWCS24 https://t.co/Gc6TKtmOgI
Dr. John Cush RheumNow ( View Tweet)
Higher adipose in RA linked to atherosclerosis but protects against erosions RWCS24 https://t.co/qsFMhj4LyZ
Dr. John Cush RheumNow ( View Tweet)
Dr Jon Giles at #RWCS24 shows adipose tissue produces pro inflammatory ytokines https://t.co/8NMAWIODuQ
Dr. John Cush RheumNow ( View Tweet)
Co-management of Psoriatic Disease
It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. Co-management with dermatology optimises the care of this patient group.
https://t.co/8xZ9ZBpa3O https://t.co/xMYLhxA1j1
Dr. John Cush RheumNow ( View Tweet)
RWCS 2024 is Kicked off by Dr Artie Kavaugh in Maui. Watch for tweets from #RWCS24 #ValentinesDay https://t.co/iPKIfXphrx
Dr. John Cush RheumNow ( View Tweet)
NJ leads on prior authorization legislation:
- Prior auth turnaround time is 24 hrs urgent requests
- Peer-to-peers for denials involves same specialty MD
- Transparency: companies have to share data on denials/reasons.
(29 states w/ active bills/reforms) https://t.co/pZlyW68DDL https://t.co/uc251qj2Gf
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety and Efficacy in bDMARD-IR Patients With RA
This ACR 2023 poster shows SELECT-CHOICE outcomes through Week 204 from bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes.
Sponsored by AbbVie US Medical Affairs. https://t.co/3fJsZ4IMjG https://t.co/xaKlZPmDkC
Dr. John Cush RheumNow ( View Tweet)
Tonix is developing a drug, TNX-102 SL, that targets poor sleep quality for fibromyalgia. Phase 3 trial in FM (457 pts) showed TNX-102 SL was better (vs PBO) & improved sleep quality (p=0.0000001 & improved daily pain (p=0.00005) https://t.co/QpgET61Vec https://t.co/zphVycL3rg
Dr. John Cush RheumNow ( View Tweet)
Taiwan National Health claims data looked at drugs & gout flares. Signif increase flares were seen w/ ASA, thiazides, loop diuretics, ethambutol, pyrazinamide (1.15-3.35) & metformin (SR=1.14). Lower risk w/ fenofibrate (SR=0.60) & losartan (0.92) https://t.co/1RUw1Q2EBz https://t.co/D2E68kuuwN
Dr. John Cush RheumNow ( View Tweet)
Microbiome study (stool- & saliva) in 144 DMARD-naïve RA pts. Samples 6 wks after DMARD Rx. In those achieving MCID, stool microbes decreased (Prevotella, Streptococcus). Baseline microbiota in DMARD-naïve pts indicated future response https://t.co/PQJEp3bNBE https://t.co/jV5SeNd21z
Dr. John Cush RheumNow ( View Tweet)
85 Chinese SLE pts study of Dz activity & depression/ anxiety assessed by PHQ-9 & GAD-7. Good correlation betw SLEDAI-2K & SLE-DAS (r=0.76);also w/ mod-high activity (r=0.79), but less w/ mild Dz/remission (r=0.45). Anxiety/Depresion did not affect scores https://t.co/eyhgiYxf3P https://t.co/5LHg3HO21v
Dr. John Cush RheumNow ( View Tweet)
Retro study of 1,169 pts (age 66 yrs) receiving intra-articular steroids & changes on A1C. A1C increases were assoc w/ higher baseline A1C (OR 1.84) for A1C 7–8 (vs <7%) or A1C >8% (OR 4.8 ). YET most patients do not experience increase A1C after IACS https://t.co/t3OWYeT1gr https://t.co/qi5qIUZQdZ
Dr. John Cush RheumNow ( View Tweet)
14d study of 30 #RA pts collected data from iPhone + Apple smartwatch +PROs showed that AI analysis of sensor data augmented PRO data (by 10%) regarding RA status & severity. Sensor + PRO correlated well w/ RAPID3 status (r2, 0.692) https://t.co/3izpHiqRHG https://t.co/vMvtqOZCjF
Dr. John Cush RheumNow ( View Tweet)
VITAL Info on Autoimmune Disease
Dr. Jack Cush reviews the journal reports from the past week on https://t.co/V10S4oVFsv. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
https://t.co/2553GYCfui https://t.co/y1seBTYk5u
Dr. John Cush RheumNow ( View Tweet)
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/cOeg3KL8Z3 https://t.co/pPRqD7PkXB
Dr. John Cush RheumNow ( View Tweet)
JAKi Rx pts w/ H.Zoster who continue JAKi are not at higher risk for recurrent HZ. 3947 (RA>UC pts on JAKi, 611 had HZ (8.38/100PY). 460 continued JAKi, 78 D/C. Recurrent HZ reactivation. after median 1.1 yrs was 5.3/100 vs. 5.9/100 PY; P = 0.52) https://t.co/FH0ysEkGiA https://t.co/lOHyaXzAn3
Dr. John Cush RheumNow ( View Tweet)